VB
Vikas Bhardwaj
Medical Technologist, AIIMS New Delhi
Updated: Apr 17, 2026
**Core Concept**
The question is testing the student's understanding of monoclonal gammopathy of undetermined significance (MGUS), a condition characterized by the presence of a monoclonal immunoglobulin peak in serum electrophoresis without evidence of end-organ damage or malignancy. MGUS is a precursor to multiple myeloma, lymphoma, or amyloidosis, but in this case, the patient's normal physical examination, laboratory results, and lack of end-organ damage suggest that the condition is benign.
**Why the Correct Answer is Right**
The diagnosis of MGUS is typically made when a monoclonal immunoglobulin peak is detected on serum electrophoresis, but the patient does not have any evidence of end-organ damage, such as anemia, renal insufficiency, bone lesions, or hypercalcemia. In this case, the patient's normal physical examination, CBC, electrolytes, renal function, and calcium level support the diagnosis of MGUS. The bone-marrow aspirate showing 5% plasma cells is also consistent with MGUS, as the percentage of plasma cells is typically below 10% in this condition. The absence of osteolytic lesions on skeletal survey further supports the diagnosis of MGUS, as these lesions are more commonly seen in multiple myeloma.
**Why Each Wrong Option is Incorrect**
**Option A:** Multiple myeloma is unlikely in this case, as the patient's normal physical examination, laboratory results, and lack of end-organ damage do not suggest an active malignancy.
**Option B:** Amyloidosis is also unlikely, as there is no evidence of end-organ damage or specific clinical features suggestive of amyloidosis.
**Option C:** Lymphoma is unlikely, as the bone-marrow aspirate shows only 5% plasma cells, which is not typical of lymphoma.
**Clinical Pearl / High-Yield Fact**
MGUS is a benign condition, but it is a precursor to multiple myeloma, lymphoma, or amyloidosis. Patients with MGUS should be followed closely with regular serum electrophoresis and bone-marrow biopsies to monitor for progression to a malignant condition.
**Correct Answer:** D.